Quantcast

Latest Neuroendocrine tumor Stories

2008-12-15 07:00:00

SAN DIEGO, Dec. 15 /PRNewswire/ -- Cylene Pharmaceuticals today announced the initiation of a Phase II clinical trial of quarfloxin (CX-3543) in patients with carcinoid/neuroendocrine tumors (C/NET), which are malignant cancers arising from neural crest cells. "Quarfloxin (CX-3543) is a small molecule that disrupts a protein:rDNA complex that forms in the abnormal nucleoli of cancer cells, thereby selectively inducing apoptotic cell death in cancers," said Dr. William Rice, President...

2008-11-13 06:00:08

* Drug Candidate Will Advance to Phase 2 Clinical Trial in Carcinoid Patients * Potent Reduction in Serotonin Achieved * Drug Candidate Being Developed Under Fast Track Status From FDA THE WOODLANDS, Texas, Nov. 13, 2008 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has successfully completed a second Phase 1 clinical trial of...

2008-10-22 09:00:10

Neotropix(R), Inc., a clinical-stage development company focused on neuroendocrine cancer treatments, announced today exciting data from an extensive pediatric preclinical study performed by the National Cancer Institute (NCI) funded Pediatric Preclinical Testing Program on the use of NTX-010 (Seneca Valley Virus-001), a tumor-selective naturally-occurring oncolytic virus. The results support the initiation of clinical development of Neotropix's lead candidate, NTX-010 for the treatment of...

2008-10-10 09:00:18

Neotropix, a clinical-stage development company focused on neuroendocrine cancer treatments, has started enrolling neuroendocrine cancer patients into an expanded clinical trial of its lead candidate, NTX-010, a tumor-selective naturally-occurring oncolytic virus. The expansion phase of the study allows the clinical sites to enroll additional patients meeting the enrollment criteria to evaluate safety and efficacy across a range of related cancers. To date, the company has tested this...

2008-10-08 09:00:12

Neotropix(R), Inc., a clinical-stage development company focused on neuroendocrine cancer treatments, announced today that it has begun enrolling neuroendocrine cancer patients into an expanded clinical trial of its lead candidate, NTX-010 (SVV-001), a tumor-selective naturally-occurring oncolytic virus. Neotropix(R) also announced that it has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) of NTX-010 for the treatment of neuroendocrine tumors. After...

2008-09-22 15:00:14

GE Healthcare Ryan Fitzgerald 414.530.2735 (m) ryan.fitzgerald@ge.com Logo: http://www.gehealthcare.com GE Healthcare, a unit of General Electric Company (NYSE:GE), today announced that the Food and Drug Administration (FDA) has approved AdreView(TM) (Iobenguane I 123 Injection), a molecular imaging agent for the detection of rare neuroendocrine tumors in children and adults. AdreView provides high quality images that allow physicians to detect tumors, both at the time of initial...

2008-09-22 12:00:38

GE Healthcare, a unit of General Electric Company, has announced that the FDA has approved AdreView, a molecular imaging agent for the detection of rare neuroendocrine tumors in children and adults. GE Healthcare said that AdreView provides high quality images that allow physicians to detect tumors, both at the time of initial diagnosis and at later examinations when relapse or recurrence is suspected. According to the company, AdreView images reflect the functional behavior of the tumor...

2008-09-09 09:00:09

Novartis has announced that RAD001 has been granted priority review by the FDA. The designation is based on the drug's potential to become the first therapy to demonstrate significant benefit in patients with advanced kidney cancer after failure of standard treatment. Novartis has also filed marketing authorization applications for RAD001 with the European Medicines Agency (EMEA) and the Swiss Agency for Therapeutic Products (Swissmedic). The proposed brand name for RAD001, Afinitor, has...

2008-08-30 09:00:21

By Tischler, Arthur S * Context.-Advances in genetics and gene expression profiling have led to new ways of thinking about the pathobiology of pheochromocytoma and extra-adrenal paraganglioma. These developments are concurrent with the publication and dissemination of the 2004 World Health Organization bluebook on pathology and genetics of endocrine tumors. Objective.-To summarize new information required by pathologists for effective participation in patient management and research. Data...

2008-08-30 09:00:20

By Chetty, Runjan * Context.-Although somewhat uncommon, neuroendocrine tumors of the gastrointestinal tract and pancreas have come under scrutiny in recent times. With advances in imaging techniques, more of these tumors are being removed and sent for pathologic evaluation. It is important for the diagnostic pathologist to be aware of recent developments in this field. Objective.-This overview focuses on nomenclature/terminology, classification, practical issues related to recent...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related